The new policy will be
priced at current rates.
Not exact matches
Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build
rates of certain aircraft; 6) the effect on aircraft demand and build
rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange
rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future
pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount
rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase
price for our announced acquisition of Asco on favorable terms or
at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit
ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest
rates increase substantially; 27) the effectiveness of any interest
rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign
current exchange
rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
At that
rate, the
current supply glut will continue and
prices should stay within a relatively tight range.
He
rates the stock «underperform» — Wall Street speak for sell — as he believes it is overvalued even
at current depressed
prices, citing the risk that investors» sentiment on the company will sour further if it is accused of fraud or «other impropriety» surfaces.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and
price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering
prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or
at all, for new and
current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock
price, corporate or other market conditions; fluctuations in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
These risks include, in no particular order, the following: the trends toward more high - definition, on - demand and anytime, anywhere video will not continue to develop
at its
current pace or will expire; the possibility that our products will not generate sales that are commensurate with our expectations or that our cost of revenue or operating expenses may exceed our expectations; the mix of products and services sold in various geographies and the effect it has on gross margins; delays or decreases in capital spending in the cable, satellite, telco, broadcast and media industries; customer concentration and consolidation; the impact of general economic conditions on our sales and operations; our ability to develop new and enhanced products in a timely manner and market acceptance of our new or existing products; losses of one or more key customers; risks associated with our international operations; exchange
rate fluctuations of the currencies in which we conduct business; risks associated with our CableOS ™ and VOS ™ product solutions; dependence on market acceptance of various types of broadband services, on the adoption of new broadband technologies and on broadband industry trends; inventory management; the lack of timely availability of parts or raw materials necessary to produce our products; the impact of increases in the
prices of raw materials and oil; the effect of competition, on both revenue and gross margins; difficulties associated with rapid technological changes in our markets; risks associated with unpredictable sales cycles; our dependence on contract manufacturers and sole or limited source suppliers; and the effect on our business of natural disasters.
If we take the median forecast of $ US 19 / tonne
at 2000
prices, add inflation and convert to CAD
at current exchange
rates, that works out to about $ C 25 / tonne.
The reality is that one doesn't need interest
rates reasonably estimate 10 - year prospective market returns, just as one doesn't need interest
rates to calculate that a $ 100 expected payment in 10 years,
at a
current price of $ 65, will result in an expected total return of 4.4 % over the coming decade.
At the same time, the
current level of the exchange
rate represents a big shift in relative
prices, which should provide substantial ongoing assistance for the export sector (and the import - competing sector).
Marriott Vacation Club, a global leader in vacation ownership, has completed the sale of the hotel component of the Surfers Paradise Marriott Resort & Spa in Queensland, Australia to Bensonlily Surfers Paradise Pty Ltd for a gross sale
price of $ 70 million AUD (approximately $ 50 million USD
at current exchange
rates).
I kept a 10 % discount
rate and still find some value
at the
current price.
I pass on probably 99 % of the ideas I look
at, many of which are great businesses, simply because the
current price won't allow my investment in the stock to compound
at the
rate of return that I'm -LSB-...]
Returns
at public offering
price (after sales charge) for class A and class M shares reflect the
current maximum initial sales charges of 5.75 % and 3.50 % for equity funds and Putnam Multi-Asset Absolute Return Fund, and 4.00 % and 3.25 % for income funds (1.00 % and 0.75 % for Putnam Floating
Rate Income Fund, Putnam Absolute Return 100 Fund, Putnam Fixed Income Absolute Return Fund, and Putnam Short - Term Municipal Income Fund), respectively.
Put simply, even taking account of
current interest
rate levels, and even assuming that stocks should be
priced to deliver commensurately lower long - term returns, we currently estimate that the S&P 500 is about 2.8 times the level
at which equities would provide an appropriate risk premium relative to bonds.
Given the absence of a public trading market of our common stock, and in accordance with the American Institute of Certified Public Accountants Accounting and Valuation Guide, Valuation of Privately - Held Company Equity Securities Issued as Compensation, our board of directors exercised reasonable judgment and considered numerous and subjective factors to determine the best estimate of fair value of our common stock, including independent third - party valuations of our common stock; the
prices at which we sold shares of our convertible preferred stock to outside investors in arms - length transactions; the rights, preferences, and privileges of our convertible preferred stock relative to those of our common stock; our operating results, financial position, and capital resources;
current business conditions and projections; the lack of marketability of our common stock; the hiring of key personnel and the experience of our management; the introduction of new products; our stage of development and material risks related to our business; the fact that the option grants involve illiquid securities in a private company; the likelihood of achieving a liquidity event, such as an initial public offering or a sale of our company given the prevailing market conditions and the nature and history of our business; industry trends and competitive environment; trends in consumer spending, including consumer confidence; and overall economic indicators, including gross domestic product, employment, inflation and interest
rates, and the general economic outlook.
In fact, given that the U.S. labor market likely experienced its cyclical peak
at the end of 2015 and the Fed began raising
rates too late in my opinion,
current Fed Funds futures are
pricing in essentially only one hike in 2016, according to data accessible via Bloomberg.
Many (including me) believe the reason that both stock
prices and real estate
prices are currently trading
at historically high valuation ratios is tied to the Feds
current «experiment» in holding interest
rates at almost zero for half a decade and running....
Dividend
rate at market
price is calculated by annualizing the most recent dividend paid and dividing it by the
current market
price.
For example, the Stumberg Ranch 55H well achieved an initial 24 - hour production
rate of 3,800 barrels of oil equivalent (BOE / d), which puts that well on pace to deliver a full payout in only 12 months
at current oil and gas
prices.
Current market
pricing suggests that an interest
rate increase
at the March 14 - 15 policy meeting is all but a done deal, a move that would bring the Fed's benchmark interest
rate target range to 1.5 % -1.75 %.
As usual, I don't place too much emphasis on this sort of forecast, but to the extent that I make any comments
at all about the outlook for 2006, the bottom line is this: 1) we can't rule out modest potential for stock appreciation, which would require the maintenance or expansion of already high
price / peak earnings multiples; 2) we also should recognize an uncomfortably large potential for market losses, particularly given that the
current bull market has now outlived the median and average bull, yet
at higher valuations than most bulls have achieved, a flat yield curve with rising interest
rate pressures, an extended period of internal divergence as measured by breadth and other market action, and complacency
at best and excessive bullishness
at worst, as measured by various sentiment indicators; 3) there is a moderate but still not compelling risk of an oncoming recession, which would become more of a factor if we observe a substantial widening of credit spreads and weakness in the ISM Purchasing Managers Index in the months ahead, and; 4) there remains substantial potential for U.S. dollar weakness coupled with «unexpectedly» persistent inflation pressures, particularly if we do observe economic weakness.
Global oil producers were able to earn attractive full - cycle
rates of returns on capital employed above $ 85 per barrel, but
at current prices, the industry is being forced to significantly pare back drilling activity.
If sellers want to buy in Bitcoins, the
price will be based on the day of the offer
at current value
rates according to the Canadian virtual exchange and the weighted
price of 12 hours.
On the other hand, for resource producers, production will be highly profitable
at current exchange
rates, given developments in resource
prices.
Summary: Based on the statewide median home
price and
current mortgage
rates, the average mortgage payment in California will be approximately $ 2,542
at the start of 2017.
Conversely, as interest
rates fall,
prices of outstanding bonds rise until their yield matches that of new bonds issued
at the
current rate.
The
prices on religionclothing.com include VAT
at the
current rate.
With the crazy exchange
rate at the moment, $ 40million euros is only 28.5 m GBP so he is well within Wenger's
price range, and if he continues to improve
at his
current rate then this could prove to be a very solid investment for the club.
The 27 year - old has a reported
price tag of # 50m and is said to have a salary bill of 10 million euros, (which as about the same as Arsene Wenger earns
at the
current exchange
rate), but he has scored a very respectable 101 goals in his last 149 games which is not a bad
rate of return, and he should be worth every penny.
The hydropower is provided
at rates that are more than 50 percent less than
current wholesale market
prices in the State.
Within 10 years,
at the
current rate of decline, a fully sequenced human genome will
price out
at less than $ 10.
The cost for the project would be roughly $ 50 million, if sequencing
prices keep falling
at the
current rate.
The subscription
prices for the Partner's web - sites on the Dating Factory network will be determined
at the sole discretion of Dating Factory according to its then
current pricing policies and may be modified from time to time to maximize conversion and retention
rates.
At the
current price and exchange
rates, it's about $ 26 USD shipped to the United States and $ 36 CAD shipped to Canada.
But
at $ 20 digital and $ 30 physical for
current gen and $ 30 digital and $ 40 physical for next gen version, this prologue comes
at quite a steep
price rate.
The reproduction fabric will be
priced at 184.45 Euros (roughly $ 229
at current exchange
rates) per 1,000 x 1,400 mm (3.2 x 4.5 foot) sheet.
Priced from $ 446,250 (# 358,499
at current exchange
rates), the SLS GT3 45th Anniversary edition will come with the option of an on - track coaching session
at an AMG driving event.
The company's first concept is an electric (no surprise there) SUV (nor there), which our sister site Auto Express suggests will have a starting
price of around $ 45,000, or in the region of # 33,000
at current exchange
rates.
All that runs to $ 16,995, on top of the Z06's $ 79,000 base
price — equivalent to around # 10,900 on top of # 50,500
at current exchange
rates.
Three will be made, and they have already been snapped up, despite the Veneno's asking
price — three million euros plus local taxes (around # 3.1 million
at current exchange
rates)-- making it over three times as costly as the # 866,000, 903bhp McLaren P1.
On the British market the model will be
priced at # 18,825 or about $ 30,000
at the
current exchange
rates.
Prices start from $ 79,968 (including 19 percent VAT), which is equivalent to $ 89,256
at the
current exchange
rates.
Ford also announced the new RS is now available to order with
prices in Germany starting from $ 39,000 - about $ 43,000
at the
current exchange
rates.
The TT RS Plus Roadster has a list
price of $ 63,500 ($ 84,500
at the
current exchange
rates) with the manual transmission and $ 65,650 ($ 86,000
at the
current exchange
rates) with the seven - speed S tronic.
In Germany, the TT - RS Coupe equipped with a manual transmission will be
priced at $ 60,650 ($ 80,500
at the
current exchange
rates) and $ 62,800 ($ 83,500
at the
current exchange
rates) with the seven - speed S - Tronic.
Pricing is expected to slot in
at around 26,000 pounds in the U.K., or $ 35,114
at current exchange
rates (1/10/2018).
Japan will be receiving five of these special 2017 Corvette Grand Sport Admiral Blue Heritage Editions
at a
price of 12,800,000 yen which is equal to around $ 115,000 USD
at current exchange
rates.
Prices for the new A3 Cabriolet will start from $ 31,700 (about $ 42,000
at the
current exchange
rates) for the 1.4 TFSI version.
As far as the
price tag is concerned, those interested in buying the 2015 Subaru Levorg will have to settle for a starting sticker of # 27,495, or $ 42,840
at current exchange
rates.
The E350 CDI Power Diesel Coupe is
priced at $ 58,534 (roughly $ 75,800
at the
current exchange
rates) and the CLS 350 CDI Power Diesel is
priced at $ 68,879 ($ 89,100).